MedTrace Logo

A Clinical Trial to Evaluate the Efficacy and Safety of LANLUMA V to Improve Jawline Contour Deficit

NCT06391580 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 192

Last updated 2024-04-30

No results posted yet for this study

Summary

A Multi-center, Randomized, No-treatment Controlled, Evaluator-blinded, Superiority Clinical Trial to Evaluate the Efficacy and Safety of LANLUMA V to Improve Jawline Contour Deficit

Conditions

  • Jawline Contour Deficit

Interventions

DEVICE

Poly-L-lactin Acid (PLLA) Based Facial Injectable

Poly-L-lactin Acid (PLLA) Based Facial Injectable

Sponsors & Collaborators

  • Sinclair Pharmaceuticals Limited

    lead INDUSTRY

Principal Investigators

  • Hongyi Zhao · Beijing Hospital, China

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-04-30
Primary Completion
2024-04-30
Completion
2025-04-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06391580 on ClinicalTrials.gov